Milvexian: all 25 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• A Study of Milvexian Using an IV Microtracer With Additional Formulation and Food Effect Comparison in Healthy ParticipantsCompletedNCT04965389Phase 1Results posted
• A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement SurgeryCompletedNCT03891524Phase 2Results posted
• A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and ClopidogrelCompletedNCT03766581Phase 2Results posted
• A Study to Evaluate Safety of Single Doses of BMS-986177 in Patients With End Stage Renal Disease (ESRD) Treated With HemodialysisCompletedNCT03000673Phase 1/2Results posted
• A Study of Milvexian Versus Apixaban in Participants With Atrial FibrillationActive, not recruitingNCT05757869Phase 3
• A Study of Milvexian in Participants After a Recent Acute Coronary SyndromeCompletedNCT05754957Phase 3
• A Study of Milvexian in Healthy Adult FemalesCompletedNCT05706753Phase 1
• A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKEActive, not recruitingNCT05702034Phase 3
• A Study of JNJ-70033093 (Milvexian) in Healthy Adult ParticipantsCompletedNCT04844424Phase 1
• A Study of JNJ-70033093 (BMS-986177) in Healthy Chinese Adult ParticipantsCompletedNCT04569695Phase 1
• A Study of JNJ-70033093 in Healthy ParticipantsCompletedNCT04448964Phase 1
• A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy ParticipantsCompletedNCT04388501Phase 1
• A Study of JNJ-70033093 (BMS-986177) in Healthy Adult ParticipantsCompletedNCT04223349Phase 1
• A Study of JNJ-70033093 and Digoxin in Healthy ParticipantsCompletedNCT04206488Phase 1
• Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male ParticipantsCompletedNCT03939702Phase 1
• A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy SubjectsCompletedNCT03698513Phase 1
• Evaluate the Pharmacokinetics of BMS-986177 From Two Formulations in Healthy ParticipantsCompletedNCT03362437Phase 1
• An Investigational Study to Assess the Effect of BMS-986177 on Aspirin in Healthy ParticipantsCompletedNCT03341390Phase 1
• To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese ParticipantsCompletedNCT03224260Phase 1
• Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal ImpairmentCompletedNCT03196206Phase 1
• Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy ParticipantsCompletedNCT02982707Phase 1
• A Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics of BMS-986177 in Healthy SubjectsCompletedNCT02959060Phase 1
• A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis TreatmentCompletedNCT02902679Phase 1
• A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Pharmacokinetics of BMS-986177 in Healthy SubjectsCompletedNCT02807909Phase 1
• Safety and Tolerability Study of BMS-986177 in Healthy SubjectsCompletedNCT02608970Phase 1

← Milvexian overview